Study of MB07811 in Subjects With Hypercholesterolemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A Phase 2 randomized, placebo controlled study assessing the efficacy, safety, and tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12 weeks followed by a 6-week off drug phase.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypercholesterolemia |
Drug: MB07811 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia |
- Evaluate the effects of MB07811 compared to placebo on LDL-C [ Time Frame: 12-weeks of treatment ] [ Designated as safety issue: No ]
- Evaluate the effects of MB07811 on other lipid markers compared to placebo [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
- Assess the safety and tolerability of MB07811 [ Time Frame: after 12 weeks of treatment and during off-drug phase ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
MB07811 Cohort 1
|
Drug: MB07811
Oral
|
|
Experimental: 2
MB07811 Cohort 2
|
Drug: MB07811
Oral
|
|
Experimental: 3
MB07811 Cohort 3
|
Drug: MB07811
Oral
|
|
Placebo Comparator: 4
Cohort 4
|
Drug: Placebo
Oral
|
Detailed Description:
This is an outpatient, Phase 2, multicenter, double-blind, placebo-controlled, randomized, parallel-group study assessing the efficacy, safety, and tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12 weeks. There will be a 3- to 6-week screening/run-in period, including washout of any lipid-modifying therapies (as needed) prior to randomization. Eligible subjects will be randomized (1:1:1:1) to placebo, or 3 different doses of MB07811 for 12 weeks. After the double-blind treatment phase, all randomized subjects will proceed into a 6-week off-drug phase. Assessments include: laboratory tests, adverse events (AEs), electrocardiograms (ECGs), vitals, and PK samples.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Body mass index (BMI) 18.50 - 40 kg/m2 inclusive at screening;
- Fasting serum LDL-C ≥145 mg/dL at both Q2 and Q3 visits;
- Fasting mean serum LDL-C <220 mg/dL from Q2 and Q3;
Exclusion Criteria:
- History of clinically significant cardiovascular disease
- Uncontrolled hypertension
- Significant sinus bradycardia defined as <40 beats per minute (bpm);
- Personal or family history of clinically significant unexplained syncope, near-syncope or unexplained sudden death or QT syndrome;
- Holter monitor report demonstrating any abnormality that is clinically significant, including but not limited to PVC frequency > 1 per minute, any alert criteria or any other condition that requires further evaluation;
- History of clinical significant arrhythmia;
- Resting 12-lead ECG showing QTc >450 msec or <360 msec (males or females), any tachyarrhythmia or morphology change, or any other clinically significant abnormality;
- Any other cardiovascular event requiring hospitalization;
- History or presence of thyroid disorder or other metabolic/endocrine disorder that affects lipids or glucose; Exceptions: polycystic ovarian syndrome (PCOS) and impaired glucose tolerance (IGT) are allowed.
- Liver disease, gallbladder disease, Gilbert's syndrome, biopsy-proven nonalcoholic steatohepatitis (NASH), positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C antibodies; Exceptions: gallbladder disease treated with cholecystectomy
- History of human immunodeficiency virus (HIV);
- Subjects with a prior history of malignancy in past 5 years;Exceptions: Subjects with previous history of basal or squamous cell carcinoma of the skin, or cervical cancer in situ are allowed if successfully treated;
- History of myopathy, including any history of statin-induced myopathy;
- History of intolerance to statins (e.g., myalgias, elevated liver tests);
- History of clinically significant psychiatric disorders, including but not limited to bipolar disorder, major depressive disorder, psychosis;
- Renal dysfunction;
- Alcohol and/or drug abuse within 12 months prior to screening;
Contacts and Locations| United States, California | |
| Scripps Clinic, Clinical Research | |
| San Diego, California, United States, 92128 | |
| United States, Florida | |
| Jacksonville Center for Clinical Research | |
| Jacksonville, Florida, United States, 32216 | |
| University Clinical Research | |
| Pembroke Pines, Florida, United States, 33024 | |
| United States, Illinois | |
| Radiant Research | |
| Chicago, Illinois, United States, 60654 | |
| United States, Indiana | |
| Midwest Institute for Clinical Research | |
| Indianapolis, Indiana, United States, 46260 | |
| United States, Kentucky | |
| Commonwealth Biomedical Research | |
| Madisonville, Kentucky, United States, 42431 | |
| United States, Michigan | |
| Troy Internal Medicine | |
| Troy, Michigan, United States, 48098 | |
| United States, South Carolina | |
| Coastal Carolina Research Center, Inc. | |
| Goose Creek, South Carolina, United States, 29445 | |
| United States, Texas | |
| Research Across America | |
| Dallas, Texas, United States, 75234 | |
| United States, Virginia | |
| National Clinical Research - Norfolk | |
| Norfolk, Virginia, United States, 23502 | |
| National Clinical Research | |
| Richmond, Virginia, United States, 23294 | |
| Study Director: | Trish Novak, Ph.D. | Metabasis Therapeutics, Inc. |
More Information
No publications provided
| Responsible Party: | Director, Project Management, Ligand Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00879112 History of Changes |
| Other Study ID Numbers: | MB07811-201 |
| Study First Received: | April 8, 2009 |
| Last Updated: | August 10, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Ligand Pharmaceuticals:
|
Hyperlipidemia |
Additional relevant MeSH terms:
|
Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013